Clinical Studies Support the Use of Longport's Technology

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency, high-resolution ultrasound imaging, today announced that 
      two papers have recently been published in peer-reviewed journals that 
      report on the utilization of Longport’s 
      EPISCAN system.
    
    
      The first paper, published in the November/December 2006 issue of Advances 
      in Skin & Wound Care, presents the use of Longport’s 
      EPISCAN for imaging the pathology of early-stage pressure ulcers and the 
      utility of high-resolution ultrasound in the early detection of this 
      condition.
    
    
      This paper concludes, “A better understanding 
      of the pathogenesis of pressure ulcers through the use of 
      high-resolution ultrasound to detect soft tissue damage and edema before 
      visible clinical signs could lead to earlier and more focused pressure 
      ulcer prevention programs, resulting in reduced pain and suffering for 
      improved patient quality of life and wound care cost savings.”
    
    
      The full reference to this paper is: Use of High-Resolution, 
      High-Frequency Diagnostic Ultrasound to Investigate the Pathogenesis of 
      Pressure Ulcer Development. Advances in Skin & Wound Care. 
      19(9):498-505, November/December 2006.
    
    
      The second paper, published in the Tissue Viability Supplement of the 
      British Journal of Nursing, reports on a case study using 
      high-resolution ultrasound to assess chronic wounds. One of the key 
      points of this paper is, “High-frequency 
      ultrasound could be used to image and quantify changes in the wounds as 
      a means of non-invasively visualizing wound characteristics which would 
      otherwise be missed using standard visual assessments alone.”
    
    
      The full reference to this paper is: Has Packing Sinus Wounds Become a 
      Ritualistic Practice? British Journal of Nursing - Volume 15, 
      Number 19: 26 October-8 November 2006. Tissue Viability Supplement, 
      pages S27-30.
    
    
      Further details on both papers can be viewed at the News section of 
      Longport’s website: http://www.longportinc.com/about/news.html.
    
    
      “These studies contribute to the validation of 
      our technology essential for the documentation of positive clinical 
      outcomes, clinical acceptance and clinical use,” 
      said Connie Phillips-Jones, RN, MSN Longport’s 
      Director of Clinical Support.
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high-resolution ultrasound imaging. After 
      several years and a multimillion dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high-resolution ultrasound imaging system. For further 
      information please contact Longport, Inc. at 1-800-289-6863 or visit our 
      website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward-Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.